| 90901-0 |
HIV 1 RNA reverse transcriptase & protease & integrase gene |
Seq |
Ser/Plas/Bld |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 RNA reverse transcriptase and protease and integrase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90901-0 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV 1 RNA RT + PR + IN SerPlBld-Seq |
|
|
|
|
|
AIDS; Blood; high-throughput sequencing; HIV 1 RNA RT + PR + IN; HIV type 1; HIV type I; HIV1; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; Pl; PlasBld; Plasma; Plsm; Point in time; PR; Random; REV; Ribonucleic acid; RT; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90902-8 |
HIV 1 RNA reverse transcriptase gene |
Seq |
Ser/Plas/Bld |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 RNA reverse transcriptase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90902-8 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV 1 RNA RT SerPlBld-Seq |
|
|
|
|
|
AIDS; Blood; high-throughput sequencing; HIV 1 RNA RT; HIV type 1; HIV type I; HIV1; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; Pl; PlasBld; Plasma; Plsm; Point in time; Random; REV; Ribonucleic acid; RT; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90903-6 |
HIV 1 RNA integrase gene |
Seq |
Ser/Plas/Bld |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 RNA integrase gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90903-6 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV 1 RNA IN SerPlBld-Seq |
|
|
|
|
|
AIDS; Blood; high-throughput sequencing; HIV type 1; HIV type I; HIV1; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; Pl; PlasBld; Plasma; Plsm; Point in time; Random; Ribonucleic acid; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90904-4 |
HIV 1 RNA protease gene |
Seq |
Ser/Plas/Bld |
Pt |
Nom |
Sequencing |
|
ACTIVE |
HIV 1 RNA protease gene [Nucleotide sequence] in Serum, Plasma or Blood by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90904-4 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
HIV 1 RNA PR SerPlBld-Seq |
|
|
|
|
|
AIDS; Blood; high-throughput sequencing; HIV type 1; HIV type I; HIV1; HTS; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Next generation sequencing; NGS; Nominal; Pl; PlasBld; Plasma; Plsm; Point in time; PR; Random; Ribonucleic acid; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90905-1 |
ABO & Rh group |
Type |
Bld^Mother |
Pt |
Nom |
|
|
ACTIVE |
Mother's ABO and Rh group Type |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
90905-1 |
|
|
|
|
Both |
|
|
|
0 |
ABO + Rh Bld Mother |
|
|
|
|
|
ABO + Rh; ABO group and Rh type; ABO+Rh Gp; Blood; BLOOD BANK; D phenotyping; D typing; Hematology; Heme; Mat; Maternal; Matnl; Nominal; Point in time; Random; Rh phenotyping; Rh typing; Typ; WB; Whole blood |
2.72 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90906-9 |
ABO & Rh group |
Type |
Bld^Father |
Pt |
Nom |
|
|
ACTIVE |
Father's ABO and Rh group Type |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
90906-9 |
|
|
|
|
Both |
|
|
|
0 |
ABO + Rh Bld Father |
|
|
|
|
|
ABO + Rh; ABO group and Rh type; ABO+Rh Gp; Blood; BLOOD BANK; D phenotyping; D typing; Hematology; Heme; Nominal; Point in time; Random; Rh phenotyping; Rh typing; Typ; WB; Whole blood |
2.72 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90907-7 |
Direct antiglobulin test.IgG specific reagent^post transfusion reaction |
PrThr |
RBC |
Pt |
Ord |
|
|
ACTIVE |
Direct antiglobulin test.IgG specific reagent [Presence] on Red Blood Cells --after transfusion reaction |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
90907-7 |
|
|
|
|
Both |
|
|
|
0 |
DAT IgG-Sp Reag p transf rx RBC Ql |
|
|
|
|
|
After; Antiglob; BLOOD BANK; DAGT; DAT; DAT IgG-Sp Reag; DCT; Dir; Direct Coomb; Direct coombs test; Erythrocytes; Hematology; Heme; Immune globulin G; Immunoglobulin G; Ordinal; p transf; p transf rx; Point in time; PR; PST; QL; Qual; Qualitative; Random; React; Red blood cells; Red blood corpusles; Rxn; Screen; Spec; Transf React; Tx |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90908-5 |
Eicosapentaenoate+Docosapentaenate w3+Docosahexaenoate/Fatty acids.C14-C22 risk |
Imp |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Eicosapentaenoate (C20:5w3)+Docosapentaenate (C22:5w3)+Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 risk [Interpretation] in Blood Qualitative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
90908-5 |
|
|
|
|
Observation |
|
|
|
0 |
EPA+DPA+DHA/FA.C14-C22 risk Bld Imp |
|
|
|
|
|
Acd; Acid; Blood; C20:5w3; C22:5w3; C22:6w3; Cervonate; Cervonic acid; Chemistry; DHA; Docosahexaenoic acid; Docosapentaenic acid; DPA; Eicosapentaenoic acid; EPA; EPA+DPA+DHA; Fatty acid; Icosapentaenoate; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Lipid; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Timnodonate; Timnodonic Acid; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90909-3 |
Arachidonate/Eicosapentaenoate |
MRto |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Arachidonate (C20:4w6)/Eicosapentaenoate (C20:5w3) [Mass Ratio] in Blood |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
90909-3 |
|
|
|
|
Observation |
|
|
|
0 |
AA/EPA Bld |
|
|
|
|
|
5,8,11,14 Eicosatetraenoic acid; AA; Arachidonic acid; Arch acid; Blood; C20:4w6; C20:5w3; Chemistry; Eicosapentaenoic acid; Eicosatetraenoate; EPA; Icosapentaenoate; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Timnodonate; Timnodonic Acid; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 9091-0 |
Sodium intake |
SRat |
^Patient |
12H |
Qn |
|
|
ACTIVE |
Sodium intake 12 hour |
|
MIN |
DefinitionDescription |
|
|
mol/12 H |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9091-0 |
|
|
|
|
|
|
|
|
0 |
Sodium intake 12h |
|
|
|
|
|
12 hours; 12HR; IO_INTAKE_SALTS+CALORIES; Na; Na+; QNT; Quan; Quant; Quantitative; Salt intake; sRate; Substance Rate; Table salt |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/(12.h) |
|
|
|
0 |
| 90910-1 |
Fatty acids.omega 6/Fatty acids.omega 3 |
MRto |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Omega 6 fatty acids (w6)/Omega 3 fatty acids (w3) [Mass Ratio] in Blood |
|
ADD |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
90910-1 |
|
|
|
|
Observation |
|
|
|
0 |
w6 FA/w3 FA Bld |
|
|
|
|
|
Acd; Acid; Blood; Chemistry; Fatty acid; III; Lipid; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; w3 FA; w6 FA; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 90911-9 |
Eicosapentaenoate+Docosapentaenate w3+Docosahexaenoate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Eicosapentaenoate (C20:5w3)+Docosapentaenate (C22:5w3)+Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90911-9 |
|
|
|
|
Observation |
|
|
|
0 |
EPA+DPA+DHA/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
Acd; Acid; Blood; C20:5w3; C22:5w3; C22:6w3; Cervonate; Cervonic acid; Chemistry; DHA; Docosahexaenoic acid; Docosapentaenic acid; DPA; Eicosapentaenoic acid; EPA; EPA+DPA+DHA; Fatty acid; Icosapentaenoate; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Timnodonate; Timnodonic Acid; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90912-7 |
Eicosapentaenoate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Eicosapentaenoate (C20:5w3)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90912-7 |
|
|
|
|
Observation |
|
|
|
0 |
EPA/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
Acd; Acid; Blood; C20:5w3; Chemistry; Eicosapentaenoic acid; EPA; Fatty acid; Icosapentaenoate; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Timnodonate; Timnodonic Acid; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90913-5 |
Docosapentaenate w3/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Docosapentaenate (C22:5w3)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90913-5 |
|
|
|
|
Observation |
|
|
|
0 |
DPA/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
Acd; Acid; Blood; C22:5w3; Chemistry; Docosapentaenic acid; DPA; Fatty acid; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90914-3 |
Docosahexaenoate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Docosahexaenoate (C22:6w3)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90914-3 |
|
|
|
|
Observation |
|
|
|
0 |
DHA/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
Acd; Acid; Blood; C22:6w3; Cervonate; Cervonic acid; Chemistry; DHA; Docosahexaenoic acid; Fatty acid; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90915-0 |
Arachidonate+Linoleate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Arachidonate (C20:4w6)+Linoleate (C18:2w6)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90915-0 |
|
|
|
|
Observation |
|
|
|
0 |
AA+Linoleate/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
5,8,11,14 Eicosatetraenoic acid; AA; AA+Linoleate; Acd; Acid; Arachidonic acid; Arch acid; Blood; C18:2w6; C20:4w6; Chemistry; cis-9, cis-12-octadecadienoate; cis-9, cis-12-octadecadienoic acid; Eicosatetraenoate; Fatty acid; Linoleic acid; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90916-8 |
Arachidonate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Arachidonate (C20:4w6)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90916-8 |
|
|
|
|
Observation |
|
|
|
0 |
AA/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
5,8,11,14 Eicosatetraenoic acid; AA; Acd; Acid; Arachidonic acid; Arch acid; Blood; C20:4w6; Chemistry; Eicosatetraenoate; Fatty acid; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90917-6 |
Linoleate/Fatty acids.C14-C22 |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Linoleate (C18:2w6)/Fatty acids.C14-C22 in Blood |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
90917-6 |
|
|
|
|
Observation |
|
|
|
0 |
Linoleate/Fatty acids.C14-C22 MFr Bld |
|
|
|
|
|
Acd; Acid; Blood; C18:2w6; Chemistry; cis-9, cis-12-octadecadienoate; cis-9, cis-12-octadecadienoic acid; Fatty acid; Linoleic acid; Lipid; Mass fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 90918-4 |
Fatty acid omega-3 & omega-6 panel |
- |
Bld |
Pt |
- |
|
|
ACTIVE |
Fatty acid omega-3 and omega-6 panel - Blood |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
90918-4 |
|
|
|
|
Order |
|
|
|
0 |
FA omega-3 + omega-6 panel Bld |
|
|
|
|
|
Acd; Acids; Blood; Chemistry; DHA; Docosahexaenoate; Docosapentaenic acid; DPA; Eicosapentaenoate; EPA; FA omega-3 + omega-6 panel; III; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; WB; Whole blood |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 90919-2 |
Coagulation factor VIII.recombinant.bound/von Willebrand factor Ag |
RelRto |
Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Coagulation factor VIII.recombinant.bound/von Willebrand factor (vWf) Ag in Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
COAG |
|
90919-2 |
|
IA |
|
|
Both |
|
|
|
0 |
Fact VIII.recomb.bound/vWF Ag Plas IA |
|
|
|
|
|
AHF; AHG; Antihemophilic factor; Antihemophilic globulin; Associated; bnd; Circulating anticoagulant; Coag; EIA; ELFA; ELISA; Enzyme immunoassay; F8; Fac; Fact; Fact VIII; Fact VIII.recomb.bound; Factor 8; Factor VIII clotting activity; FVIII; Hematology; Heme; IAA; MEIA; Normandy; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Relative ratio; SUDS; Thrombocyte cofactor A; Type 2 Normandy; VIII:C; Von will; Vonwillebrand; vWf; vWF:Ag |
2.68 |
2.65 |
|
|
|
|
|
|
|
{ratio} |
|
|
Release 2.68: LONG_COMMON_NAME: Removed extra "Ag" |
0 |
| 9092-8 |
Sodium intake |
SRat |
^Patient |
24H |
Qn |
|
|
ACTIVE |
Sodium intake 24 hour |
|
MIN |
DefinitionDescription |
|
|
mol/24 H |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9092-8 |
|
|
|
|
|
|
|
|
0 |
Sodium intake 24h |
|
|
|
|
|
1 day; 24 hours; 24HR; IO_INTAKE_SALTS+CALORIES; Na; Na+; QNT; Quan; Quant; Quantitative; Salt intake; sRate; Substance Rate; Table salt |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/(24.h) |
|
|
|
0 |
| 90920-0 |
Lysophosphatidylcholine(20:0) |
MCnc |
Bld.dot |
Pt |
Qn |
|
|
ACTIVE |
Lysophosphatidylcholine(20:0) [Mass/volume] in DBS |
|
ADD |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHEM |
|
90920-0 |
|
|
|
|
Observation |
|
|
|
0 |
LysoPC(20:0) DBS-mCnc |
|
|
|
|
|
Blood; Chemistry; DBS; Dried blood spot; Filter paper; FP; Level; LysoPC(20:0); Mass Concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 90921-8 |
Lysophosphatidylcholine(22:0) |
MCnc |
Bld.dot |
Pt |
Qn |
|
|
ACTIVE |
Lysophosphatidylcholine(22:0) [Mass/volume] in DBS |
|
ADD |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHEM |
|
90921-8 |
|
|
|
|
Observation |
|
|
|
0 |
LysoPC(22:0) DBS-mCnc |
|
|
|
|
|
Blood; Chemistry; DBS; Dried blood spot; Filter paper; FP; Level; LysoPC(22:0); Mass Concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 90922-6 |
Lysophosphatidylcholine(24:0) |
MCnc |
Bld.dot |
Pt |
Qn |
|
|
ACTIVE |
Lysophosphatidylcholine(24:0) [Mass/volume] in DBS |
|
ADD |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHEM |
|
90922-6 |
|
|
|
|
Observation |
|
|
|
0 |
LysoPC(24:0) DBS-mCnc |
|
|
|
|
|
Blood; Chemistry; DBS; Dried blood spot; Filter paper; FP; Level; LysoPC(24:0); Mass Concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 90923-4 |
Lysophosphatidylcholine(26:0) |
MCnc |
Bld.dot |
Pt |
Qn |
|
|
ACTIVE |
Lysophosphatidylcholine(26:0) [Mass/volume] in DBS |
|
ADD |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHEM |
|
90923-4 |
|
|
|
|
Observation |
|
|
|
0 |
LysoPC(26:0) DBS-mCnc |
|
|
|
|
|
Adrenoleukodystrophies; Adrenoleukodystrophies, X-Linked; Blood; C26:0; C26:0-LPC; Chemistry; DBS; Dried blood spot; Filter paper; FP; Level; LysoPC(26:0); Mass Concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood; X-ALD |
2.65 |
2.65 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
